Trial results

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875 on ClinicalTrials.gov · last registry update 2026-10-13

A small phase 3 — 150 participants, against a typical 424. Due to report December 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Mass Index (BMI). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status

RECRUITING

Phase

P3

Drug

tirzepatide

Mounjaro, Zepbound

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

150

Started

2026-09-25

Primary completion

2029-12 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percent Change from Baseline in Body Mass Index (BMI)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.